Gene therapy achieves therapeutic benefits by delivering genetic materials, packaged within a delivery vehicle, to target cells with defective genes. This approach has shown promise in treating various conditions, including cancer, metabolic disorders, and tissue degenerative diseases. Over the past five years, molecular imaging has increasingly supported gene therapy development in both preclinical and clinical studies. High-quality images from positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and computed tomography (CT) enable quantitative and reliable monitoring of gene therapy. Most reported studies have applied imaging biomarkers to non-invasively evaluate the outcomes of gene therapy. This review aims to inform researchers in molecular imaging and gene therapy about the integration of these two disciplines. We highlight recent developments in using imaging biomarkers to monitor the outcome of in vivo gene therapy, where the therapeutic delivery vehicle is systemically administered. In addition, we discuss prospects for further incorporating imaging biomarkers to support the development and application of gene therapy.

中文翻译：

---

体内基因治疗结果转化成像的最新进展。


基因疗法通过将包装在递送载体内的遗传物质递送到具有缺陷基因的靶细胞来实现治疗效果。这种方法在治疗各种疾病方面显示出前景，包括癌症、代谢紊乱和组织退行性疾病。在过去的五年中，分子成像越来越多地支持临床前和临床研究中基因疗法的发展。来自正电子发射断层扫描 （PET）、单光子发射计算机断层扫描 （SPECT）、磁共振成像 （MRI） 和计算机断层扫描 （CT） 的高质量图像能够对基因治疗进行定量和可靠的监测。大多数报道的研究都应用成像生物标志物来无创评估基因治疗的结果。本综述旨在告知分子影像学和基因治疗的研究人员这两个学科的整合。我们重点介绍了使用成像生物标志物监测体内基因治疗结果的最新进展，其中治疗递送载体是系统给药的。此外，我们讨论了进一步结合成像生物标志物以支持基因疗法的开发和应用的前景。